ATE198277T1 - Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator - Google Patents

Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator

Info

Publication number
ATE198277T1
ATE198277T1 AT93923080T AT93923080T ATE198277T1 AT E198277 T1 ATE198277 T1 AT E198277T1 AT 93923080 T AT93923080 T AT 93923080T AT 93923080 T AT93923080 T AT 93923080T AT E198277 T1 ATE198277 T1 AT E198277T1
Authority
AT
Austria
Prior art keywords
stabilizer
production
active substance
factor viii
composition including
Prior art date
Application number
AT93923080T
Other languages
English (en)
Inventor
Thomas Oesterberg
Angelica Fatouros
Original Assignee
Genetics Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9202878A external-priority patent/SE9202878D0/xx
Priority claimed from SE9301580A external-priority patent/SE9301580D0/xx
Priority claimed from SE9302006A external-priority patent/SE9302006D0/xx
Application filed by Genetics Inst filed Critical Genetics Inst
Application granted granted Critical
Publication of ATE198277T1 publication Critical patent/ATE198277T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT93923080T 1992-10-02 1993-10-01 Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator ATE198277T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE9202878A SE9202878D0 (sv) 1992-10-02 1992-10-02 Protein formulation
SE9301580A SE9301580D0 (sv) 1993-05-07 1993-05-07 Protein formulation
SE9302006A SE9302006D0 (sv) 1992-10-02 1993-06-11 Protein formulation
PCT/SE1993/000793 WO1994007510A1 (en) 1992-10-02 1993-10-01 Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer

Publications (1)

Publication Number Publication Date
ATE198277T1 true ATE198277T1 (de) 2001-01-15

Family

ID=27355693

Family Applications (2)

Application Number Title Priority Date Filing Date
AT93923080T ATE198277T1 (de) 1992-10-02 1993-10-01 Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
AT99121997T ATE316981T1 (de) 1992-10-02 1993-10-01 Zusammensetzung, welche den koagulationsfaktor viii beinhalted; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT99121997T ATE316981T1 (de) 1992-10-02 1993-10-01 Zusammensetzung, welche den koagulationsfaktor viii beinhalted; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator

Country Status (19)

Country Link
US (2) US5733873A (de)
EP (3) EP0627924B1 (de)
JP (1) JP3905921B2 (de)
KR (1) KR100303872B1 (de)
AT (2) ATE198277T1 (de)
CA (1) CA2124690C (de)
CZ (1) CZ290342B6 (de)
DE (2) DE69329795T2 (de)
DK (1) DK0627924T3 (de)
ES (1) ES2154650T3 (de)
FI (1) FI111443B (de)
GR (1) GR3035472T3 (de)
HU (2) HU220194B (de)
MX (1) MX9306133A (de)
NO (1) NO942033D0 (de)
NZ (1) NZ256921A (de)
PT (1) PT627924E (de)
SK (1) SK282483B6 (de)
WO (1) WO1994007510A1 (de)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE198277T1 (de) * 1992-10-02 2001-01-15 Genetics Inst Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
SE504074C2 (sv) † 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US6288030B1 (en) * 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
US6242417B1 (en) * 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
US5514781A (en) * 1994-04-11 1996-05-07 Bayer Corporation Use of azoles as virucidal agents in solutions of biologically active proteins
US6372716B1 (en) * 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
SE503424C2 (sv) * 1994-11-14 1996-06-10 Pharmacia Ab Process för rening av rekombinant koagulationsfaktor VIII
US7253262B2 (en) 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
GB9501040D0 (en) * 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US7244824B2 (en) 1995-01-19 2007-07-17 Quadrant Drug Delivery Limited Dried blood factor composition comprising trehalose
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
EP1820516B1 (de) 1999-02-22 2013-07-24 University of Connecticut Neue albuminfreie Faktor VIII Formulierungen
US20060099685A1 (en) * 1999-04-15 2006-05-11 Yallop Christopher A Recombinant expression of factor VIII in human cells
EP1194161B1 (de) 1999-07-13 2005-11-23 Biovitrum Ab Zusammensetzungen mit stabilem faktor viii
US6413537B1 (en) * 2000-03-10 2002-07-02 Wisconsin Alumni Research Foundation Nystatin formulation having reduced toxicity
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
AU2003293543A1 (en) * 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
US8541002B2 (en) 2003-09-12 2013-09-24 Agenus Inc. Vaccine for treatment and prevention of herpes simplex virus infection
PL1750733T3 (pl) 2004-05-03 2014-05-30 Univ Emory Sposób podawania świńskiego czynnika krzepnięcia VIII pozbawionego domeny B
KR100624013B1 (ko) * 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
DK2371856T3 (en) 2004-11-12 2022-08-08 Bayer Healthcare Llc Site-directed modifikation af FVIII
AU2005322067B8 (en) 2004-12-27 2012-07-26 Takeda Pharmaceutical Company Limited Polymer-von Willebrand factor-conjugates
JP2008539208A (ja) 2005-04-28 2008-11-13 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 活性化型のｖｉｉ因子ポリペプチドを含んでいる閉鎖容器、調製する方法、並びにキットおよび前記キットを使用する方法
ES2393117T3 (es) 2005-09-12 2012-12-18 Actelion Pharmaceuticals Ltd. Composición farmacéutica estable que comprende una pirimidina-sulfamida
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
WO2007126808A1 (en) * 2006-03-31 2007-11-08 Baxter International Inc Pegylated factor viii
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
US7985839B2 (en) * 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
US7982010B2 (en) * 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
DK2101821T3 (da) 2006-12-15 2014-10-06 Baxter Healthcare Sa Faktor VIIA-(poly)sialinsyre-konjugat med forlænget halveringstid in vivo
EP2150264A4 (de) 2007-04-26 2014-09-24 Bayer Healthcare Llc Stabilisierung flüssiger lösungen eines rekombinanten proteins für gefrorene lagerung
SI2574677T1 (sl) 2007-12-27 2017-11-30 Baxalta GmbH Procesi celične kulture
EP2113564A1 (de) * 2008-05-01 2009-11-04 Arecor Limited Proteinformulierung
WO2010020690A1 (en) 2008-08-21 2010-02-25 Octapharma Ag Recombinantly produced human factor viii and ix
KR101691070B1 (ko) * 2008-09-03 2016-12-29 옥타파마 아게 재조합에 의해 제조된 인자 ⅷ을 위한 신규한 보호 조성물
AU2009303368B2 (en) * 2008-10-15 2012-04-05 Takeda Pharmaceutical Company Limited Pegylation of recombinant blood coagulation factors in the presence of bound antibodies
EP2385825B1 (de) 2008-11-07 2018-10-10 University of Connecticut Faktor-viii-formulierungen
LT2379104T (lt) 2008-12-31 2018-04-10 Revance Therapeutics, Inc. Injekcinės botulino toksino vaisto formos
DK3178835T3 (da) 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
DK3266463T3 (da) 2009-06-09 2024-01-08 Prolong Pharmaceuticals Llc Hæmoglobinsammensætninger
US10172950B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
US10172949B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
CN102869373B (zh) 2009-06-25 2017-05-10 雷文斯治疗公司 不含白蛋白的肉毒杆菌毒素制剂
RU2744370C2 (ru) 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
EP3081233B1 (de) 2009-07-27 2020-12-23 Baxalta GmbH Glycopolysialylierung von proteinen ausser blutgerinnungsproteinen
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
BR112012001814A8 (pt) 2009-07-27 2018-02-06 Baxalta GmbH Conjugados de proteína de coagulação sanguínea
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
GB0915480D0 (en) * 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
TWI534152B (zh) 2010-07-30 2016-05-21 巴克斯特國際公司 用於肟連接的親核性催化劑
BR112013011041B1 (pt) 2010-11-05 2021-05-25 Baxalta GmbH variante de fator viii, método para produzir uma variante de fviii, uso da variante de fator viii, e, composição farmacêutica
EP2652491B1 (de) 2010-12-15 2017-11-29 Baxalta GmbH Eluatsammlung mit leitfähigkeitsgradient
WO2012079979A1 (en) * 2010-12-16 2012-06-21 Novo Nordisk A/S Aqueous factor viii solution
ES2800983T3 (es) 2010-12-22 2021-01-07 Baxalta GmbH Materiales y métodos para conjugar un derivado de ácido graso soluble en agua con una proteína
WO2013123457A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
CN111548418A (zh) 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
AU2013204754C1 (en) 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
US9212357B2 (en) 2012-12-03 2015-12-15 Omrix Biopharmaceuticals Ltd. Thrombin solution and methods of use thereof
ES2926798T3 (es) * 2013-03-15 2022-10-28 Bioverativ Therapeutics Inc Formulaciones de polipéptido de factor VIII
SG11201505926VA (en) 2013-03-15 2015-09-29 Biogen Ma Inc Factor ix polypeptide formulations
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
ES2819217T3 (es) 2013-09-08 2021-04-15 Kodiak Sciences Inc Conjugados de polímeros iónicos dipolares y factor VIII
EA201691111A1 (ru) 2014-01-10 2017-01-30 Байоджен Ма Инк. Химерные белки фактора viii и их применение
NZ722391A (en) 2014-02-04 2022-12-23 Biogen Ma Inc Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
EA202092926A3 (ru) 2014-03-24 2021-10-29 Биовератив Терапьютикс Инк. Лиофилизированные составы, содержащие фактор ix
US12180264B2 (en) 2014-03-24 2024-12-31 R-Pharm Overseas, Inc. IL1-R1 derived inhibitor of IL-1β and use thereof
US9907835B2 (en) 2014-04-01 2018-03-06 Advanced Bioscience Farmacêutica LTDA Stable Factor VIII formulations with low sugar-glycine
CN106456720A (zh) * 2014-04-01 2017-02-22 爱德技术生物科学有限公司 在无钙作为赋形剂下因子viii的稳定性
DK3193911T5 (da) * 2014-07-25 2024-10-14 Csl Behring Gmbh Forbedrede faktor VII-præparater til brug ved behandling af hæmofili A
JP6516829B2 (ja) * 2014-08-04 2019-05-22 シーエスエル、リミテッド 第ｖｉｉｉ因子製剤
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
EP3294324A1 (de) 2015-05-13 2018-03-21 Agenus Inc. Impfstoffe zur behandlung und prävention von krebs
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
UA126016C2 (uk) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Злитий білок фактора іх
CN108348458A (zh) * 2015-11-05 2018-07-31 诺和诺德股份有限公司 Fviii制剂
EP3167877A1 (de) 2015-11-12 2017-05-17 Bayer Pharma Aktiengesellschaft Verfahren zur herstellung von gefriergetrockneten pellets mit faktor viii
TW201731869A (zh) 2015-12-03 2017-09-16 百克莎塔股份有限公司 具有延長之半衰期及降低之配位體結合性質的因子ｖｉｉｉ
KR20190090827A (ko) 2016-12-02 2019-08-02 바이오버라티브 테라퓨틱스 인크. 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
WO2019074886A1 (en) 2017-10-09 2019-04-18 Terumo Bct Biotechnologies, Llc LYOPHILIZATION CONTAINER AND METHOD OF USE
EP3784688A2 (de) 2018-04-26 2021-03-03 Agenus Inc. Hitzeschockproteinbindende peptidzusammensetzungen und verfahren zu deren verwendung
KR102914074B1 (ko) 2018-05-18 2026-01-16 바이오버라티브 테라퓨틱스 인크. A형 혈우병의 치료 방법
US11609042B2 (en) 2019-03-14 2023-03-21 Terumo Bct Biotechnologies, Llc Multi-part lyophilization container and method of use
WO2021001522A1 (en) 2019-07-04 2021-01-07 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
BR112022022089A2 (pt) * 2020-05-22 2022-12-13 R Pharm Overseas Inc Composição de proteína heterodimérica, composição terapêutica que compreende a mesma e uso da dita composição para tratar uma doença associada à modulação de il-1ss
EP4240757A2 (de) 2020-11-09 2023-09-13 Takeda Pharmaceutical Company Limited Reinigung von fviii aus plasma mittels siliciumoxidadsorption
TW202317178A (zh) * 2021-06-23 2023-05-01 美商百歐維拉提夫治療公司 因子ⅷ嵌合蛋白的配製品及其用途
EP4415693B1 (de) * 2021-10-15 2026-02-18 Bioverativ Therapeutics Inc. Formulierungen von chimären faktor-viii-proteinen und verwendungen davon
CN116350801A (zh) * 2022-11-22 2023-06-30 四川至善唯新生物科技有限公司 一种重组腺相关病毒载体的药物组合物及其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4165370A (en) * 1976-05-21 1979-08-21 Coval M L Injectable gamma globulin
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
DE3176491D1 (en) * 1980-03-05 1987-11-26 Miles Lab Pasteurized therapeutically active protein compositions
US4481189A (en) * 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
SE8501050D0 (sv) * 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
US4758657A (en) * 1985-07-11 1988-07-19 Armour Pharmaceutical Company Method of purifying Factor VIII:C
CA1292686C (en) * 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
FR2630115B1 (fr) * 1988-04-14 1994-10-28 Merieux Inst Procede de stabilisation des solutions d'albumine humaine et solution obtenue
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US4996047A (en) * 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes
ATE108326T1 (de) * 1989-01-30 1994-07-15 Corint Ltd Wässerige desmopressin-cmc enthaltende arzneizubereitung.
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
ATE198277T1 (de) * 1992-10-02 2001-01-15 Genetics Inst Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator

Also Published As

Publication number Publication date
DK0627924T3 (da) 2001-04-30
ATE316981T1 (de) 2006-02-15
EP0627924B1 (de) 2000-12-27
EP1016673B1 (de) 2006-02-01
CZ290342B6 (cs) 2002-07-17
DE69329795D1 (de) 2001-02-01
AU5288393A (en) 1994-04-26
AU677797B2 (en) 1997-05-08
DE69333974T2 (de) 2006-08-03
WO1994007510A1 (en) 1994-04-14
KR100303872B1 (ko) 2001-11-22
PT627924E (pt) 2001-05-31
FI942573A0 (fi) 1994-06-01
ES2154650T3 (es) 2001-04-16
FI111443B (fi) 2003-07-31
JPH07501560A (ja) 1995-02-16
NZ256921A (en) 1996-05-28
MX9306133A (es) 1994-04-29
EP1652534A3 (de) 2007-05-02
SK65994A3 (en) 1995-03-08
EP1652534A2 (de) 2006-05-03
EP1016673A1 (de) 2000-07-05
NO942033L (no) 1994-06-01
DE69333974D1 (de) 2006-04-13
SK282483B6 (sk) 2002-02-05
HU9401382D0 (en) 1994-08-29
FI942573L (fi) 1994-06-01
HU220194B (hu) 2001-11-28
US5919766A (en) 1999-07-06
NO942033D0 (no) 1994-06-01
CA2124690A1 (en) 1994-04-14
HU211670A9 (en) 1995-12-28
CA2124690C (en) 2007-09-11
GR3035472T3 (en) 2001-05-31
DE69329795T2 (de) 2001-07-05
HUT70330A (en) 1995-09-28
JP3905921B2 (ja) 2007-04-18
EP0627924A1 (de) 1994-12-14
CZ132894A3 (en) 1994-11-16
US5733873A (en) 1998-03-31

Similar Documents

Publication Publication Date Title
ATE316981T1 (de) Zusammensetzung, welche den koagulationsfaktor viii beinhalted; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
DE69005394D1 (de) Zusammensetzungen welche komplexe von hyaluronsäure enthalten und verfahren zu deren herstellung.
ATE243995T1 (de) Nanoemulsion von dem öl-in-wasser typ, gebrauchbar als ein ophthalmischen vehikel und verfahren zur seiner herstellung
GR900100481A (el) Μέ?οδος παρακευής υδατικού αιωρήματος για ουσιαστικά αδιάλυτους στο νερό ενεργούς παράγοντες.
ATE72229T1 (de) Verfahren zur herstellung von serin-n,ndiessigs|ure und derivaten.
AT371819B (de) Verfahren zur herstellung von neuen trans-4,4a,5, 6,7,8,8a,9-octahydro-1h (und 2h)-pyrazolo(3,4-g) chinolinen, deren isomeren und den saeureadditionssalzen hiervon
EP0767657A4 (de) Neues verfahren zur herstellung von bekannten und neuen 2'-modifizierten nukleosiden durch intramolekulare nukleophile substitution
ATE137735T1 (de) Substituierte cyclohexan-derivate, verfahren zu ihrer herstellung und die anwendung der verbindungen zur behandlung von krankheiten
ATE86978T1 (de) Verfahren zur herstellung von 3,5-dimethyl-4methoxypyridinderivaten sowie neues zwischenprodukt hierfuer.
ATA84992A (de) Verfahren zur herstellung einer hochgereinigten virussicheren faktor viii-präparation
ES2026314A6 (es) Procedimiento para obtener una composicion profilactica antimicrobiana oftalmica neonatal.
ATE159183T1 (de) Flüssige, konzentrierte, wässrige lösungen von alkylethercarbonsäuresalzen und verfahren zu ihrer herstellung
DE59301163D1 (de) Spulenkörper und verfahren zu dessen herstellung
ATE188690T1 (de) N-aryl-3-aryl-4-substituierte-4,5-dihydro-1h- pyrazol-1-carboxamide und verfahren zu deren herstellung
DE59510180D1 (de) Verfahren zur Herstellung von 4-Amino-2,2,6,6-tetramethyl-piperidin
EP0400429A3 (de) Verfahren zur Herstellung von Triphendioxazinen
DE59006295D1 (de) Verfahren zur Herstellung perfluorierter heterocyclischer Verbindungen und nach diesem Verfahren hergestellte Verbindungen.
DE69123248D1 (de) Verfahren zur herstellung einer wässrigen suspension
DE59501060D1 (de) Verfahren zur Herstellung von 2,5-Dihydrofuran
ATE247962T1 (de) Wässrige zusammensetzungen mit ciprofloxacin, verfahren zu deren herstellung und deren verwendung
EP0271099A3 (de) Substituierte Aminopropionsäureamide, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und ihre Verwendung sowie die bei der Herstellung anfallenden neuen Zwischenprodukte
DE69811893D1 (de) Verfahren zur herstellung von azetidin-2-carbonsäure und zwischenprodukten davon
PT77825A (de) Neue 2-azabicyclo<2.2.1>heptan-derivate verfahren zu ihrer herstellung diese enthaltende mittel und deren verwendung sowie 2-azabicyclo/2.2.1/heptan-derivate als zwischenprodukte und verfahren zu deren herstellung
DE59509651D1 (de) Verfahren zur Herstellung von 2,5-Dihydrofuran
CA2394241A1 (fr) Procede d'additivation minimisant la segregation des additifs et leur migration

Legal Events

Date Code Title Description
EEFA Change of the company name